669 related articles for article (PubMed ID: 30261606)
1. Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response.
Gilabert-Oriol R; Ryan GM; Leung AWY; Firmino NS; Bennewith KL; Bally MB
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261606
[TBL] [Abstract][Full Text] [Related]
2. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
Gabizon A; Martin F
Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
[TBL] [Abstract][Full Text] [Related]
3. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
4. Liposomes targeting tumour stromal cells.
Kuijpers SA; Coimbra MJ; Storm G; Schiffelers RM
Mol Membr Biol; 2010 Oct; 27(7):328-40. PubMed ID: 20939769
[TBL] [Abstract][Full Text] [Related]
5. Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours.
Cheng YQ; Wang SB; Liu JH; Jin L; Liu Y; Li CY; Su YR; Liu YR; Sang X; Wan Q; Liu C; Yang L; Wang ZC
Cell Prolif; 2020 Aug; 53(8):e12865. PubMed ID: 32588948
[TBL] [Abstract][Full Text] [Related]
6. Sodium bicarbonate nanoparticles modulate the tumor pH and enhance the cellular uptake of doxorubicin.
Abumanhal-Masarweh H; Koren L; Zinger A; Yaari Z; Krinsky N; Kaneti G; Dahan N; Lupu-Haber Y; Suss-Toby E; Weiss-Messer E; Schlesinger-Laufer M; Shainsky-Roitman J; Schroeder A
J Control Release; 2019 Feb; 296():1-13. PubMed ID: 30615983
[TBL] [Abstract][Full Text] [Related]
7. Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy.
Muntimadugu E; Kommineni N; Khan W
Pharmacol Res; 2017 Dec; 126():109-122. PubMed ID: 28511988
[TBL] [Abstract][Full Text] [Related]
8. Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells.
Ahmed N; Escalona R; Leung D; Chan E; Kannourakis G
Semin Cancer Biol; 2018 Dec; 53():265-281. PubMed ID: 30317036
[TBL] [Abstract][Full Text] [Related]
9. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system.
Chen B; Dai W; Mei D; Liu T; Li S; He B; He B; Yuan L; Zhang H; Wang X; Zhang Q
J Control Release; 2016 Nov; 241():68-80. PubMed ID: 27641831
[TBL] [Abstract][Full Text] [Related]
10. Ligand-targeted liposomal therapies of neuroblastoma.
Pastorino F; Marimpietri D; Brignole C; Di Paolo D; Pagnan G; Daga A; Piccardi F; Cilli M; Allen TM; Ponzoni M
Curr Med Chem; 2007; 14(29):3070-8. PubMed ID: 18220743
[TBL] [Abstract][Full Text] [Related]
11. Immunogenic cell death in cancer therapy: Present and emerging inducers.
Zhou J; Wang G; Chen Y; Wang H; Hua Y; Cai Z
J Cell Mol Med; 2019 Aug; 23(8):4854-4865. PubMed ID: 31210425
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A; Shmeeda H; Barenholz Y
Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
[TBL] [Abstract][Full Text] [Related]
13. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment.
Mikhaylov G; Mikac U; Magaeva AA; Itin VI; Naiden EP; Psakhye I; Babes L; Reinheckel T; Peters C; Zeiser R; Bogyo M; Turk V; Psakhye SG; Turk B; Vasiljeva O
Nat Nanotechnol; 2011 Aug; 6(9):594-602. PubMed ID: 21822252
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy.
Yang S; Gao H
Pharmacol Res; 2017 Dec; 126():97-108. PubMed ID: 28501517
[TBL] [Abstract][Full Text] [Related]
15. New drug delivery nanosystem combining liposomal and dendrimeric technology (liposomal locked-in dendrimers) for cancer therapy.
Gardikis K; Hatziantoniou S; Bucos M; Fessas D; Signorelli M; Felekis T; Zervou M; Screttas CG; Steele BR; Ionov M; Micha-Screttas M; Klajnert B; Bryszewska M; Demetzos C
J Pharm Sci; 2010 Aug; 99(8):3561-71. PubMed ID: 20564386
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicines for the treatment of hematological malignancies.
Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
[TBL] [Abstract][Full Text] [Related]
17. Beyond the tumour microenvironment.
Laplane L; Duluc D; Bikfalvi A; Larmonier N; Pradeu T
Int J Cancer; 2019 Nov; 145(10):2611-2618. PubMed ID: 30989643
[TBL] [Abstract][Full Text] [Related]
18. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
19. Liposomal Nanoparticles Carrying anti-IL6R Antibody to the Tumour Microenvironment Inhibit Metastasis in Two Molecular Subtypes of Breast Cancer Mouse Models.
Guo C; Chen Y; Gao W; Chang A; Ye Y; Shen W; Luo Y; Yang S; Sun P; Xiang R; Li N
Theranostics; 2017; 7(3):775-788. PubMed ID: 28255366
[TBL] [Abstract][Full Text] [Related]
20. Development of ligand-targeted liposomes for cancer therapy.
Noble CO; Kirpotin DB; Hayes ME; Mamot C; Hong K; Park JW; Benz CC; Marks JD; Drummond DC
Expert Opin Ther Targets; 2004 Aug; 8(4):335-53. PubMed ID: 15268628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
